U.S. panel backs claim Lilly diabetes drug cuts cardiac death

30 Jun 2016


Eli Lilly & Co and Boehringer Ingelheim should be allowed to claim that their diabetes drug Jardiance, also known as empagliflozin, cuts the risk of cardiovascular death, conclude an advisory panel to the U.S. Food and Drug Administration.

Reuters

 

Share this story